The data record behind the New Drug Application for intrathecal adrabetadex in infantile-onset Niemann-Pick disease type C (NPC) is a platform abstract presented by Elizabeth Berry-Kravis and colleagues at the 2026 American College of Medical Genetics and Genomics meeting and published in a Genetics in Medicine Open supplement in March 2026. It reports that infantile-onset children treated with the drug had a lower risk of death than matched external controls (n=80, hazard ratio 0.289, p<0.0001), a 71 per cent reduction as the sponsor Beren Therapeutics describes it, and that the mean annual rate of neurological progression fell by 43 per cent, or 0.58 points a year, on the rescored four-domain NPC Clinical Severity Score (n=79, p=0.006). Cerebrospinal fluid markers of neuronal damage fell in association with treatment: fatty acid binding protein 3 by 40.5 per cent (n=24, p=0.008) and total tau by 19 per cent (n=101, p=0.008). This is an abstract, not a full peer-reviewed report, and there was no concurrent control group: the survival comparison is against historical patients, and the progression figure compares each patient's treated period with their own untreated period. A Beren poster from WORLDSymposium 2026 states that 72 of the 80 treated participants were successfully matched, drawn against a pool of 255 infantile-onset external controls, with median treatment duration of 3.8 years.
Adrabetadex is a proprietary mixture of 2-hydroxypropyl-beta-cyclodextrin isomers given by lumbar puncture. It was written off once. A protocol amendment filed by Vtesse, then a Mallinckrodt company, dated 10 February 2021, records that the sponsor's benefit and risk assessment of adrabetadex had been changed to negative, with a recommendation effective 20 January 2021 that treatment be stopped as soon as possible under clinician oversight. Beren, through its subsidiary Mandos, says it acquired the programme from Mallinckrodt in 2021, and that an earlier breakthrough therapy designation granted in 2016 had been rescinded by the FDA on the basis of the 12-month phase 2b/3 trial. A new breakthrough designation followed in December 2025, the NDA was accepted for priority review in February 2026 with an action date of 17 August 2026, and on 28 May 2026 the company said the FDA had classified its 18 March 2026 response to an information request as a major amendment, moving the target decision date to 17 November 2026. The drug is not approved anywhere.
The published numbers do not fully line up. The abstract prints the survival result as hazard ratio 0.289 with a 95 per cent confidence interval of 0.049 to 0.398. Beren's own February 2026 announcement gives 0.141 to 0.593 for the same pooled hazard ratio, and 0.049 to 0.398 is the interval reported for the subgroup not taking miglustat at baseline (hazard ratio 0.139). The two cannot be reconciled from the published record. Readers should also note what the severity scale measures: the four-domain rescored score covers fine motor, gross motor, speech and swallowing, and, as an ACMG therapeutics bulletin published in December 2025 sets out, the rescored instrument excludes cognition. NPC in children brings progressive cognitive as well as motor decline, and the reported 43 per cent slowing does not speak to that domain.
On harm, the sponsor describes hearing impairment, manageable with hearing aids where needed, plus post-dose fatigue and ataxia as the main adverse events. That signal is not new. In the open-label phase 1-2 trial of intrathecal 2-hydroxypropyl-beta-cyclodextrin at the National Institutes of Health, published in The Lancet in 2017, 14 patients were enrolled and hearing loss time-locked to dosing was observed, ototoxicity having been anticipated from animal work.